New science, in plain language. Checked before you read a word.

Every two days we take 10 brand-new scholarly papers, screen each one for retractions and a live DOI, and rewrite them so a curious person can actually read them.

This screen checks process signals. It does not tell you the findings are true.

Get it free, every two days

Three papers free every issue. No spam. Leave in one click.

In this issue 10 papers · 3 free

01 Nature Regression to the mean can explain saturation of geomagnetic storms Free
02 Nature Metabolite glues as a means of purine sensing and chemotherapeutic response Free
03 Nature Medicine An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial Free
04 Nature Communications ADAPT-M: a workflow for rapid, quantitative in vitro measurements of enriched protein libraries Subscribers
05 Nature Communications Exogenous creatine supplementation promotes tumor metastasis via megakaryocyte creatine kinase B-STAT5B signaling Subscribers
06 Proceedings of the National Academy of Sciences Targeted α-synuclein mRNA degradation by PMO-based RNA-degrading chimeras Subscribers
07 Proceedings of the National Academy of Sciences Cryogenic silicification enables nongenetic functional continuity across mammalian cell generations Subscribers
08 Science A statistical test for the benefits of personalizing interventions Subscribers
09 Science Roots navigate around decay regions by sensing local pH gradients Subscribers
10 Nature Medicine Health system learning enables generalist neuroimaging models Subscribers

The papers Read free

Nature·15 July 2026

Nithin Sivadas, David Sibeck et al.

Regression to the mean can explain saturation of geomagnetic storms

Scientists once thought Earth's magnetic response to strong solar wind hits a ceiling during extreme space weather. This new study shows that "ceiling" was actually a math illusion. It comes from a common statistical trap called regression to the mean, caused by uncertain measurements of the solar wind's timing and strength. Once the errors are fixed, Earth's response keeps growing steadily with solar wind strength. It never levels off. This means the biggest geomagnetic storms could hit Earth twice as hard as scientists had believed.

Earth's magnetic storms may be twice as strong as once believed, with no true limit.

The number: The true impact of extreme geomagnetic storms can be twice as large as previously thought.
The caveat: The paper shows the old "leveling off" idea came from biased math, not real physics. But it does not rule out every other possible explanation for the original pattern.

For your life: nothing to act on yet. Early research, worth watching.

Integrity screen: passed (3 checks) Checked 15 July 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Nature). Read the source

Nature·15 July 2026

Samuel R. Witus, Megan M. Kober et al.

Metabolite glues as a means of purine sensing and chemotherapeutic response

Cells need a way to know when they have enough of a key building block called purines. This study found a natural "molecular glue" that does this job. The glue is made from purine molecules themselves. It sticks two proteins together so the cell stops making more purines once levels are high. A chemotherapy drug used since the 1950s works the same way. It sticks to the same two proteins, but in a different position, which makes it work better. The sticky spot where this happens can also change shape. This shape change may explain why some drug versions work better than others.

Cells use natural glue molecules made from purines to control their own purine production.

The number: No key statistic identified
The caveat: This research was done at the molecular and cellular level, not in whole animals or people. It cannot yet tell us how this discovery would change real patient treatment.

For your life: nothing to act on yet. Early research, worth watching.

Integrity screen: passed (3 checks) Checked 15 July 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Nature). Read the source

Nature Medicine·13 July 2026

Matteo S. Carlino, Ellen Kapiteijn et al.

An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial

A new drug shrank tumors in some patients with a rare, hard-to-treat eye cancer that spreads. This cancer often carries specific gene changes that make cells grow out of control. The drug is built to find a marker on cancer cells. It then releases a treatment inside the cell to block that growth signal. In a trial of 66 patients, 13 patients had their tumors shrink a lot. That is about 20 percent. Another 47 patients, or about 71 percent, had some tumor shrinkage. Patients went a median of 7.2 months before their cancer got worse. Serious side effects were uncommon. Only five patients, about 8 percent, had severe treatment-related problems.

A new targeted drug shrank tumors in many patients with an aggressive, spreading eye cancer.

The number: 13 of 66 patients (about 20 percent) had major tumor shrinkage; 47 of 66 (about 71 percent) had some shrinkage.
The caveat: This was an early trial with only 66 patients and no comparison group. It cannot prove the drug works better than other treatments.

For your life: If you or someone you know has this cancer, this could be a question to ask a doctor about newer treatment options.

Integrity screen: passed (3 checks) Checked 15 July 2026. Retraction record: none. DOI resolves at doi.org. Metadata record found (Nature Medicine). Read the source

7 more papers are in the full issue.

The same screening, the full reading, every two days. 2 euros a month, or 20 a year, and you can leave in one click.

Nature Communications·15 July 2026

Carla P. Perez, Nicole V. DelRosso et al.